Stefan Evers

University of Münster — Germany

Medicine · Health Sciences

25h-index3.8kcitations110works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(27), Monoclonal and Polyclonal Antibodies Research(25), Radiopharmaceutical Chemistry and Applications(15), Peptidase Inhibition and Analysis(12), Immunotherapy and Immune Responses(10)

Publications110 total

Implications for driving based on the risk of seizures after ischaemic stroke
Journal of Neurology Neurosurgery & Psychiatry·2024· 6 citedOpen Access
Table S2 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Table S1 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Supplemental legend from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Figure S2 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Figure S2 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Supplemental material from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Data from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Supplemental legend from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Table S1 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Figure S1 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Supplemental material from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Data from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Figure S1 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Figure S3 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Table S2 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Figure S3 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
2023Open Access
Buchbesprechungen
Nervenheilkunde·2022Open Access
906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
Annals of Oncology·2021· 3 cited
Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
Journal of Clinical Oncology·2021· 23 cited
page 1 of 6Next →

Frequent Co-authors

Volker Teichgräber(8), Christian Klein(7), Tapan K. Nayak(7), Wolfgang Keck(6), Hanno Langen(6), Inja Waldhauer(5), Marina Bacac(5), Pablo Umaña(5), Patrice Courvalin(5), Christopher P. Gray(5), Michael Fountoulakis(5), Christophe Boetsch(5), Jan H.M. Schellens(5), Valeria Nicolini(4), Anne Freimoser–Grundschober(4), Jose Saro(4), Karin Di Padova(4), Jehad Charo(4), Sabine M. Lang(3), Erwin van Puijenbroek(3)